The US Food and Drug Administration has approved the Scibase Pre-Market Approval (PMA) for its product Nevisense.
Nevisense is SciBase's device for the early detection of malignant melanoma. With the approval, SciBase can now market and sell Nevisense in the US. According to the letter from the